Drug Discovery & DDS– category –
-
NEOK002: Next-Generation Bispecific ADC Targeting EGFR and MUC1 Enters Clinical Development for Solid Tumors
Conference Coverage AACR USA Overview NEOK002 (formerly ABL209), a bispecific antibody-drug conjugate (ADC), has entered clinical development, designed to concurrently target two key cancer antigens, EGFR and MUC1, implicated in epitheli... -
BeOne Medicines’ BEQALZI™ (Sonrotoclax) Gains US FDA Approval for Relapsed/Refractory Mantle Cell Lymphoma as First BCL2 Inhibitor
Stock Titan USA Overview BeOne Medicines announced that BEQALZI™ (sonrotoclax) has received U.S. FDA approval for the treatment of relapsed/refractory Mantle Cell Lymphoma (MCL), marking it as the first BCL2 inhibitor for this indication... -
GSK’s Bepirovirsen for Chronic Hepatitis B Receives FDA Priority Review and Breakthrough Therapy Designation
GSK USA Overview GSK announced that its investigational antisense oligonucleotide (ASO), Bepirovirsen, a candidate for chronic Hepatitis B, has been granted both Priority Review and Breakthrough Therapy Designation (BTD) by the U.S. FDA.... -
Incyte Partners with Edison Scientific to Integrate “Kosmos” AI Platform for Enhanced Drug Discovery and Development
Investing.com Canada USA Overview Incyte has announced a partnership with Edison Scientific to integrate Edison's AI platform, "Kosmos," into its drug discovery and development processes. This collaboration focuses on target discovery, v... -
GLP-1 Gene Therapy Enters First Human Clinical Trials; Endometriosis Poised for First Disease-Modifying Treatment
DDN Magazine USA Overview This week's DDN Weekly Rundown reports that GLP-1 gene therapy has advanced into its first human clinical trials, alongside the potential emergence of the first disease-modifying therapy for endometriosis. The e... -
GLP-1 Drug Manufacturing Surges: CDMOs Scale Peptide Synthesis, Driving Technology Transfer
IntuitionLabs USA Overview Driven by soaring GLP-1 demand, Contract Development and Manufacturing Organizations (CDMOs) are rapidly expanding peptide synthesis capabilities. Industry reports project the GLP-1 peptide CDMO market to grow ... -
Samsung Biologics Labor Dispute Stalls Wage Talks, Raising Concerns for Global CDMO Competitiveness
The Elec Inc. South Korea Overview Wage negotiations between management and labor union at Samsung Biologics have reached a prolonged stalemate, raising concerns about the company's global competitiveness in the Contract Development and ... -
Polpharma Biologics and Tuteur Forge Alliance to Boost Biosimilar Access Across Latin America
Morningstar ポーランド Overview Polpharma Biologics has finalized a strategic licensing agreement with Argentina's Tuteur Pharmaceutical, granting exclusive commercialization rights for a biosimilar targeting autoimmune diseases across L... -
Thousand Oaks Biologics Honored with Forbes China Industry Award for Leading ADC CDMO Capabilities
TMX Newsfile China Overview Thousand Oaks Biologics has been awarded the "2026 Forbes China Industry Development Leading Enterprise Award" for its advanced capabilities in antibody-drug conjugate (ADC) manufacturing. Operating across Chi... -
FDA Grants Breakthrough Therapy Designation to Chronic Low Back Pain Treatment, Signaling Potential Shift for Cannabinoid-Derived Therapies
YouTube (CB1 Capital) USA Overview The U.S. FDA has granted Breakthrough Therapy Designation (BTD) for a treatment for chronic low back pain. This announcement potentially signals an emerging wave of designations for cannabinoid-derived ...
